TABLE 2.

Infusion-related events in patients receiving amphotericin B in 5% dextrose (group 1) or in Intralipid (group 2)

Event	Value for:		P	95% CI
	Group 1	Group 2
Infusion-related fever
No. of patients affected (%)	28/33 (85)	19/28 (68)	0.11	−4–38
No. of associated administrations of amphotericin B (%)	124/310 (40)	58/252 (23)	<0.0001	9–24
Median duration, days (range)	2 (0–14)	2 (0–7)	0.07
Infusion-related rigors
No. of associated administrations of amphotericin B (%)	102/310 (33)	15/252 (6)	<0.0001	21–33
Median duration, days (range)	2 (0–9)	0 (0–3)	0.004
Administration of meperidine
No. of patients receiving (%)	18/33 (54)	6/28 (21)	0.008	10–56
No. of administrations of amphotericin B requiring drug (%)	45/310 (14)	8/252 (3)	<0.0001	7–16
Hypotension, no. affected (%)	3/33 (9)	1/28 (4)	0.62	−6–17
Hypokalemia, no. affected (%)	19/33 (58)	6/28 (21)	0.004	13–59
Nephrotoxicity, no. affected (%)	7/22 (32)	4/19 (21)	0.44	−16–37
Difference between baseline and final concentrations of creatinine (mg/dl), mean	0.36	0.26	0.5